Equity Overview
Price & Market Data
Price: $9.17
Daily Change: -$0.10 / 1.09%
Range: $8.72 - $9.64
Market Cap: $309,844,224
Volume: 250,331
Performance Metrics
1 Week: 20.34%
1 Month: 18.32%
3 Months: -14.70%
6 Months: -61.74%
1 Year: -60.24%
YTD: -50.24%
Company Details
Employees: 43
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.